Physician profile
Miriam Levitt
NPI 1447247820
$7,455.70
in general payments reported to CMS, 2019-2025
46 companies · $1,378 in 2025
The $1,378 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,170 · 2022: $1,244 · 2023: $1,885 · 2024: $1,780 · 2025: $1,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,042.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,642.57 | 2021-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $1,176.10 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $754.54 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Axsome Therapeutics, INC. | $619.69 | 2023-2025 | Auvelity |
| Glaxosmithkline, LLC. | $228.03 | 2021-2025 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $218.06 | 2023-2025 | |
| Pfizer INC. | $217.26 | 2021-2025 | |
| Novo Nordisk INC | $209.99 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $202.13 | 2021-2024 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.02 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $156.63 | 2021-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.46 | 2023-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company Ltd. | $120.24 | 2022 | |
| Exact Sciences Corporation | $117.09 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Dynavax Technologies Corporation | $97.95 | 2022-2023 | Heplisav-B |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miriam Levitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.